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Abstract
Background: Financial incentives are an effective way of helping women to stop smoking during pregnancy.
Unfortunately, most women who stop smoking at this time return to smoking within 12 months of the infant’s
birth. There is no evidence for interventions that are effective at preventing postpartum smoking relapse. Financial
incentives provided after the birth may help women to sustain cessation. This randomised controlled trial will assess
the effectiveness and cost-effectiveness of financial incentives to help women who are abstinent from smoking at
end-of-pregnancy to avoid return to smoking up to 12 months postpartum.
Methods: This is a UK-based, multi-centre, three-arm, superiority, parallel group, individually randomised controlled
trial, with 1:1:1 allocation. It will compare the effectiveness of two financial incentive interventions with each other
(one intervention for up to 3 months postpartum offering up to £120 of incentives (£60 for the participant and £60
for a significant other support); the other for up to 12 months postpartum with up to £300 of incentives (£240 for
the participant and £60 for a significant other support) and with a no incentives/usual care control group. Eligible
women will be between 34 weeks gestation and 2 weeks postpartum, abstinent from smoking for at least 4 weeks,
have an expired carbon monoxide (CO) reading < 4 parts per million (ppm), aged at least 16 years, intend
remaining abstinent from smoking after the birth and able to speak and read English.
The primary outcome is self-reported, lapse-free, smoking abstinence from the last quit attempt in pregnancy until
12 months postpartum, biochemically validated by expired CO and/or salivary cotinine or anabasine. Outcomes will
be analysed by intention-to-treat and regression models used to compare the proportion of abstinent women
between the two intervention groups and between each intervention group and the control group. An economic
evaluation will assess the cost-effectiveness of offering incentives and a qualitative process evaluation will examine
barriers and facilitators to trial retention, effectiveness and implementation.
Discussion: This pragmatic randomised controlled trial will test whether offering financial incentives is effective and
cost-effective for helping women to avoid smoking relapse during the 12 months after the birth of their baby.
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Introduction
Background and rationale {6a}
More women stop smoking during pregnancy than at
any other time; around half of pregnant women who
smoke are likely to cease smoking ‘spontaneously’ [1].
This presents a valuable opportunity to help women
who stop smoking in pregnancy to stop permanently.
Most women who stop smoking in pregnancy wish to
remain abstinent after the birth [2]. However, up to
three-quarters of spontaneous quitters return to smok-
ing within 6 months of the birth [3], thereby increasing
their risks of smoking-related illness, as well as their
children’s risks of passive smoking [4, 5] and of becom-
ing smokers [6]. Behavioural support has been evaluated
as an intervention for preventing postpartum relapse to
smoking but there is no evidence for these interventions
[7]. During pregnancy, offering financial incentives has
been shown to be one of the most effective smoking ces-
sation interventions [1, 8] and it is plausible that offering
incentives in postpartum will reduce relapse to smoking.
Several studies have recruited women in early
pregnancy and examined the combined effect of offering
incentives in pregnancy and postpartum on postpartum
rates of smoking abstinence. First, a trial that
randomised women to incentives or a control group
during pregnancy (N = 43) showed that, when providing
an incentive voucher of $50 at 1 month and 2 months
postpartum (contingent upon validated abstinence),
around a third of women still relapsed by 2 months
postpartum and the rate of relapse was similar in the
control group [9]. Secondly, a non-randomised study (N
= 58) offered a $20 incentive voucher (contingent upon
abstinence) once weekly during the initial 4 weeks post-
partum and then every other week for a further 8 weeks
[10]. In the incentives vs control group, rates of abstin-
ence reduced between end-of-pregnancy (37% vs 9%)
and 24-week postpartum assessment (27% vs 0%), in
favour of the incentives group. A further trial, which
randomised women to receive incentives or not in preg-
nancy (N = 77), used the same intervention schedule as
Higgins et al. [10] except that payments could escalate
based on maintaining abstinence [11]. This study re-
ported abstinence rates for incentives vs control at end-
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of-pregnancy of 41% vs 10% and at 24-week postpartum
as 8% vs 3%. Higgins et al. (N = 118) [12] randomised
women in pregnancy and included the same intervention
as Heil et al. [11] as well as a revised condition which
provided bonuses for those who could meet a more
stringent biochemical validation criterion. The validated
abstinence rates at end-of-pregnancy and 24 weeks post-
partum, respectively, were standard incentives 36% vs
15%, revised incentives 45% vs 18% and control 18% vs
8%. In the largest study to date (N = 1014), women who
were randomised in early pregnancy were offered cash
incentives of $25–40 for each of four home visits at 1, 2,
4 and 6 weeks postpartum, $20 for each of five post-
birth counselling calls and $40 for biochemically verified
abstinence at 1 and 6 months postpartum [13]. At 6
months postpartum, 15% were validated as abstinent in
the incentives group and 9% in the control group. This
study did not report abstinence at end-of-pregnancy;
therefore, it was not possible to examine the relapse
rates. Finally, a pilot study (N = 60), randomising women
in early pregnancy, used an app-based intervention and
offered vouchers worth $33 for each validated assess-
ment conducted twice weekly during the first 4 weeks
postpartum and once weekly during a further 8 weeks
postpartum [14]. At end-of-pregnancy, validated abstin-
ence for the incentives vs control group was 37% vs 13%,
while at 24 weeks postpartum it was 20% vs 7%.
While these studies show some potential benefit of
postpartum incentives, randomisation was early in
pregnancy for women who were currently smoking;
therefore, it was not possible to examine the separate
effects of postpartum incentives on smoking cessation.
Moreover, all the studies were conducted in the US and
all, except the study by Baker et al. [13], were limited by
small sample sizes. We are conducting a UK-based large
randomised controlled trial (RCT), which is the first to
examine the specific effect of postpartum financial in-
centives on rates of postpartum relapse to smoking,
among women who received incentives in pregnancy,
were confirmed as abstinent at end-of-pregnancy and at




The primary objective of this three-arm RCT is to assess
the effectiveness of offering financial incentives to help
women who are abstinent from smoking at end-of-
pregnancy to avoid return to smoking up to 12 months
postpartum.
Hypotheses
There are four hypotheses relating to the primary
objective:
(i) That an intervention offering 1 months of
postpartum financial incentives will be significantly
more effective for aiding smoking cessation up to
12 months postpartum than a no incentives
condition.
(ii) That an intervention offering 3 months of
postpartum incentives will be significantly more
effective for aiding smoking cessation up to 12
months postpartum than a no incentives condition.
(iii)That an intervention offering 12 months of
postpartum incentives will be significantly more
effective for aiding smoking cessation up to 12
months postpartum than an intervention offering 3
months of postpartum incentives.
(iv)That there will be a significant linear trend in
smoking cessation across the three study groups,
with rates of abstinence increasing from the no
incentives group, to the 3 months incentives group,
to the 12-month incentives group.
Secondary objectives
The secondary objectives are as follows:
 To assess the effectiveness of offering financial
incentives to help women maintain smoking
abstinence until at least 3 months after birth of the
infant
 To assess whether financial incentives are cost-
effective in terms of incremental cost per quitter at
12 months postpartum
 To identify the effects of maternal characteristics
(e.g. cigarette consumption before pregnancy) and
type of smoking cessation services (i.e. midwife-led
or not) on the effectiveness of the intervention
 To explore participant’s and intervention provider’s
experiences of and views on, the intervention and
research procedures, in order to identify the barriers
and facilitators to trial/intervention retention,
effectiveness and implementation
Trial design {8}
This study is a multi-centre, three-arm, superiority,
parallel group, individually randomised controlled
trial, with 1:1:1 allocation, designed to test the effect-
iveness of offering financial incentives to help women,
who are abstinent from smoking at end-of-pregnancy,
to avoid returning to smoking up to 12 months post-
partum. In addition, an economic evaluation will
assess the cost-effectiveness of offering financial in-
centives, and a qualitative process evaluation will
examine barriers and facilitators to trial retention, ef-
fectiveness and implementation.
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Methods: participants, interventions and
outcomes
Study setting {9}
Study participants will be recruited from stop smoking
services (SSS) serving maternity hospitals in four UK
National Health Service (NHS) hospital Trusts in
Greater Manchester. All participating Trusts cover large
areas of deprivation and include a city, several provincial
towns, suburban and rural areas. This diversity facilitates
recruitment of women from different socio-economic
backgrounds. Each of these sites have different SSS con-
figurations offering their own care pathway within the
framework of the UK National Institute for Health and
Care Excellence (NICE) guidance [15]. This includes
NHS/local authority-run services, generic/specialist
pregnancy services and midwifery/SSS advisor-led ser-
vices and represents most UK usual care pathways for
smoking cessation in pregnancy. This also includes mul-
tiple care settings, from low-risk midwifery led care to
high-risk tertiary units. The total deliveries per year at
the four Trusts in 2019–2020 was 28,270, ranging from
2230 births in the smallest Trust to 12,150 in the largest
Trust. In these Trusts, again in 2019–2020, 10.7% of
women were recorded as smokers at time of delivery,
against an average across England of 10.4%.
Eligibility criteria {10}
Site eligibility: current routine care for smoking cessation in
pregnancy
Study sites are only eligible if they are currently offering
the Smokefree Pregnancy Programme in Greater
Manchester, which incorporates an offer of financial
incentives for biochemically validated smoking abstinence
through to the end of pregnancy. This section describes
this routine smoking cessation care which is offered in
Greater Manchester.
This programme includes ‘BabyClear’ [16], which
implements UK guidance [15] around smoking in
pregnancy, as well as linking NHS Trusts who provide
antenatal care and community-based providers of smok-
ing cessation support. Training is provided for maternity
staff, smoking cessation advisors and administrators
within smoking cessation services. Midwives are trained
to use CO monitoring for all women at the first ante-
natal appointment, with routine opt-out referral for
smoking cessation support for any woman with a CO re-
cording above 3 (parts per million) ppm. Babyclear also
includes an enhanced ‘risk perception’ intervention for
women who continue to smoke at their first trimester
ultrasound scan appointment, at around 12 weeks
gestation.
Women who report currently smoking, or having
stopped smoking in the last 2 weeks, and have an
expired CO reading > 3 ppm are offered regular (at least
4 weekly) support from a stop smoking advisor. Women
can be referred by maternity services to receive this
support or can self-refer. Expired CO is routinely tested
at all smoking cessation appointments and stopping
smoking is facilitated at the earliest possible point in
pregnancy, with routes back into support at any point of
relapse.
In addition to Babyclear, all the women in the
pregnancy programme are offered a financial incentives
scheme. This scheme is routine care and is not part of
the intervention for the trial. For the first 4 weeks
women are offered a £10 ‘Love2Shop’ voucher
(redeemable in many UK retail outlets) per week and
then a £20 voucher each month, up to 36 weeks
gestation. This is conditional on the woman reporting
lapse-free abstinence since their quit date and having an
expired CO reading of < 4 ppm. Additionally, participat-
ing women are given the option to recruit a ‘Significant
Other Supporter’ (SOS) (a member of their community,
including a close family member such as a partner, who
agrees to support the woman to remain smoke free, in-
cluding attending cessation support sessions) who is en-
titled to receive a £60 Love2Shop voucher if the woman
remains quit at 36 weeks gestation and the SOS is also
confirmed as abstinent (CO < 8 ppm). If a woman re-
lapses to smoking and agrees to set a new quit, she can
be re-recruited into the incentives scheme, up to 32
weeks gestation. If she relapses a second time she is no
longer eligible to participate in the scheme and is offered
support outside the scheme. The latest point at which a
women can begin a quit attempt as part of the Smoke-
free Pregnancy Programme/Babyclear is at 32 weeks ges-
tation. If a woman is referred after 32 weeks she is
offered routine support for smoking cessation in preg-
nancy without the offer of incentives (and is not eligible
for the trial). In cases of miscarriage, premature birth or
stillbirth the woman is no longer eligible for the incen-
tives scheme and is offered cessation support outside of
the scheme.
All women provided with smoking cessation support
in pregnancy are also given brief advice about
maintaining abstinence postpartum and in the long-
term.
Participant eligibility
Women who have undergone the above Smokefree
Pregnancy Programme in Greater Manchester will be
eligible to join the study if they meet the following
inclusion criteria: are between 34 weeks gestation and 2
weeks postpartum, confirm having not smoked a single
puff of a cigarette for at least 4 weeks, expired carbon
monoxide (CO) reading < 4 ppm (piCObaby™
Smokerlyzer®, Bedfont Scientific Ltd.), aged at least 16
years, intend remaining abstinent from smoking after
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the birth (or to continue remaining abstinent if recruited
postpartum), able to speak and read English and be
willing and able to give written informed consent for
participation in the study. If the participant is required
to use a single-person, self-administered carbon monox-
ide monitor (iCO) (i.e. during COVID-19 restrictions),
they require a device (e.g. phone) that is compatible with
the monitor app.
Rationale for CO cut-off of < 4 ppm
During pregnancy, when metabolism is higher and there
are respiratory changes, a CO cut-off of < 4 ppm is rec-
ommended [17, 18], whereas out of pregnancy a cut-off
of < 8 ppm is more standard [19]. Therefore, for eligibil-
ity, we used a criterion of < 4 ppm. It is not clear
whether metabolism and respiratory function would
have returned to non-pregnant levels during the first 2
weeks postpartum compared with pregnancy; therefore
we will apply the CO cut-off of < 4 ppm equally to
women who are recruited in late pregnancy and to
women who are recruited in the first 2 weeks
postpartum.
There is recent evidence that the iCO can produce a
slightly higher CO reading than more conventional CO
monitors [20]. However, the iCO has not been
compared with other monitors during pregnancy;
therefore, we retained the cut-off of < 4 ppm for the
iCO during testing for eligibility.
Who will take informed consent? {26a}
All women confirmed as abstinent by their stop smoking
service (SSS) advisor at around 36 weeks gestation
(acceptable range, 34 weeks gestation to 2 weeks
postpartum), and meeting other eligibility criteria, will
be invited by their advisor to join the study. The SSS
advisor will explain that we are running an RCT
examining the effects of offering shopping vouchers on
women’s smoking cessation during the 12 months after
their baby is born. If a face-to-face appointment is pos-
sible at this time, the SSS will ask women for their writ-
ten informed consent to participate in the trial. They
will also ask for their consent to be contacted after the
12 months follow-up to be invited to take part in an
interview to discuss their experience of the trial. It will
be made clear that women can participate in the trial
without consenting to be interviewed and that this will
not affect their participation in the trial or the usual care
that they receive.
All women who are eligible and have provided consent
to participate in the trial will be randomised to one of
the three study groups. After women are randomised,
they will be given an additional participant information
sheet (PIS) describing the specific study group they have
been allocated to.
All SSS staff will attend a half-day session, delivered by
a member of the research team, to be informed about
the trial and to be trained in taking consent, delivering
the intervention and other research procedures.
‘Distanced’ consent methods
Due to COVID-19 restrictions on face-to-face contact,
the following provisions have been made: Potential par-
ticipants can be contacted at around 32 weeks and 36
weeks gestation by phone, as well as face-to-face. The
participant information sheet and consent form can be
sent to participants by post, email or via a web-link em-
bedded within a text message. Women will be offered
several ‘distanced’ methods for providing informed
consent:
1. To post the completed written consent form to a
researcher or SSS before being randomised
2. To take a photo or scan of their completed written
consent form and texting or emailing it to a
researcher or SSS advisor
3. To provide verbal consent to join the trial. During
the call, potential participants will give explicit
verbal consent to the statements on the consent
form. An SSS advisor will then sign the participant’s
consent form and check a ‘tick box’ which notes on
the consent form that consent was taken verbally
by telephone.
Justification for distanced consent methods
We believe it is ethical to use the ‘distanced’ consent
methods described above and they have received ethical
approval. If all participants are required to receive, sign
and return signed consent forms, this will result in many
women, who wish to join the trial, not returning signed
confirmation. For example, women may be socially
isolating and do not wish to leave their homes to post
the consent form or they may not have the facility to
transfer the completed form electronically. In this
circumstance adequate recruitment and, hence, a robust
evaluation would be difficult. Moreover, a ‘hard-to-
reach’ group would lose the potential to benefit from
participation in the trial.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
No additional consent provisions are required.
Interventions
Explanation for the choice of comparators {6b}
Those in the ‘no incentives’ control group will receive
postpartum care as usual, except, as for all participants,
they will be offered a £20 voucher payment, at both 3
months and 12 months postpartum, as a gesture of
Ussher et al. Trials          (2021) 22:512 Page 5 of 16
thanks for completing a follow-up assessment. During
pregnancy, all women receive routine care for smoking
cessation in pregnancy, including the offer of incentives,
as described in section ‘Eligibility criteria {10}’. This in-
cludes brief advice about maintaining abstinence post-
partum and in the long-term. Other than this, currently
there is no routine, postpartum relapse prevention sup-
port offered to women or partners who have quit smok-
ing before or during pregnancy.
Intervention description {11a}
There are two intervention/incentive groups. The
incentive payments are in the form of Love2Shop gift
cards that can be redeemed in a wide variety of UK
shops and that are used in the pregnancy incentives
scheme that the women have participated in. Love2Shop
vouchers have been used in a previous UK trial of
incentives for smoking cessation in pregnancy [21].
During COVID-19 restrictions on face-to-face contact,
participants will attend appointments remotely, via
telephone, rather than face-to-face and smoking cessa-
tion status will be assessed remotely. Also, vouchers will
be posted to participants. See section ‘Outcomes {12}’
for details of ‘Assessing smoking cessation outcomes
during COVID-19 restrictions on face-to-face contact’.
Intervention group 1: incentives are offered up to 3 months
postpartum
This intervention is provided in addition to the usual
care as received by the ‘no incentives’ group.
Payments to participants Participants are offered a
total of £60 of incentive payments. An incentive of £20
is offered at each of the visits at 1, 2 and 3 months
postpartum. Payments are conditional on self-report of
not smoking a single puff of a cigarette since their last
quit date in pregnancy and an expired CO reading of < 8
ppm. This intervention, including the amount of incen-
tive, was chosen because it has been used previously in
the UK, including in Greater Manchester, and has been
shown to be acceptable to postpartum women and SSS
advisors [22].
Payments to significant other supporter Participants
will also be given the option to identify a ‘Significant
Other Supporter’ (SOS) (a member of their community,
including a close family member such as a partner, who
agrees to support the woman to remain smoke free,
including attending smoking cessation validation visits).
The women’s SOS will be offered an incentive of £60 if
the woman achieves CO validated abstinence at 3
months postpartum and the SOS is also confirmed as
abstinent (CO < 8 ppm), irrespective of whether the
SOS has been a smoker. During the period of COVID-
19 restrictions on face-to-face contact, the SOS will be
confirmed as abstinent based on self-report alone. Previ-
ously, SOS payments have been shown to be acceptable
to postpartum women and their partners in the UK [22]
and elsewhere [9].
The total value of incentives offered to this group,
including payments to the participant (£60) and the SOS
(£60), is £120.
Intervention group 2: incentives are offered up to 12
months postpartum
This intervention is provided in addition to the usual
care as received by the ‘no incentives’ group.
In addition to all the incentives offered to group 1,
participants in this group are offered £60 at each of the
visits at 6, 9 and 12 months postpartum. The rationale
for the amount of incentive offered in the 12-month
condition was based on repeating the payment made to
the participant at 3 months (i.e. £60) at 3-month inter-
vals (i.e. at 6, 9 and 12 months) up to 12 months. Again,
payments are dependent on expired CO confirmation of
self-reported abstinence. No additional incentive is of-
fered to the SOS beyond that offered at 3 months.
The total value of incentives offered to this group,
including those offered to the participant (£240) and
SOS (£60), is £300. This intervention was devised
specifically for this study, in order to examine the
potential benefit of continuing the offer of incentives, at
3-month intervals, up to the primary end-point at 12
months postpartum.
To our knowledge, neither of the incentive
interventions has been previously tested in a research
study. The level of incentives offered in the interventions
are between the lowest level suggested by the general
public that might be effective (£20 per month) and the
highest acceptable level (£80 per month), for during
pregnancy [23]. No such data on incentives is available
for postpartum.
Behavioural support for intervention groups
In both intervention groups, the SSS advisor is
instructed to provide only behavioural support that is
integral to the incentives intervention. In total, the
interventions include the following four behaviour
change techniques (BCTs), as defined by a standard
taxonomy of BCTs [24], and the numbering is that used
in the taxonomy:
10.1 Material incentive (behavior): Inform that a
financial incentive will be offered if the participant and
SOS reports not smoking and has a CO < 8 ppm
1.3 Goal setting (outcome): Set a goal of not smoking
a single puff of a cigarette until the next assessment
2.6 Biofeedback: Inform the person of their expired
CO reading
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10.4 Social reward: SSS congratulates person if they
remain abstinent from smoking
Adherence to the protocol for providing behavioural
support will be been explored in the interviews with
smoking cessation advisors.
Payments for attending assessments
In addition, in order to maximise completion of follow-
ups, all participants are offered a £20 voucher payment,
for completing a follow-up assessment at both 3 months
and 12 months postpartum (i.e. £20 for each
assessment).
Criteria for discontinuing or modifying allocated
interventions {11b}
There are no special criteria for discontinuing or
modifying allocated interventions.
Participants may choose to stop attending appointments
and receiving incentive payments for any reason.
Strategies to improve adherence to interventions {11c}
None beyond the brief behavioural support described in
{11a}.
Relevant concomitant care permitted or prohibited
during the trial {11d}
Trial participants are permitted to receive relapse
prevention support, during postpartum, beyond that
provided by the intervention and any additional support
is recorded. The SSS conducting the research follow-ups
are asked not to provide any relapse prevention support
at the follow-ups beyond that defined as part of the
intervention (for the description of the allowed support
see: {11} Intervention description/Behavioural support
for intervention groups).
Provisions for post-trial care {30}
None, beyond standard care within the NHS
Outcomes {12}
At the 3 and 12 months postpartum follow-ups, women
will initially be assessed for smoking status over the
phone (up to five attempts will be made to call them) by
their stop smoking service (SSS) advisor or by a re-
searcher. Those who report having not smoked a single
puff of a cigarette since their last quit date in pregnancy
will be asked to attend a face-to-face appointment with
their SSS advisor to confirm their smoking status or to
confirm their smoking status by remote means (see sec-
tion ‘Assessing smoking cessation outcomes during
COVID-19 restrictions on face-to-face contact’).
Primary outcome measure
The primary outcome is self-reported, lapse-free,
smoking abstinence from the last quit attempt in
pregnancy until 12 months postpartum, biochemically
validated by an exhaled CO reading of < 8 ppm, and/
or saliva cotinine or anabasine estimation. Where
possible, both a CO reading and saliva sample will be
collected and for a woman to be validated as abstin-
ent both the CO reading and saliva test will need to
confirm abstinence. Where both a CO reading and
saliva sample cannot be collected, either a CO reading
or a saliva test will be used to confirm abstinence.
The proportion of abstinent women will be compared
between the two intervention groups and between
each intervention group and the control group. Dur-
ing pregnancy, due to physiological changes including
higher metabolism [25], a CO cut-off of < 4 ppm is
recommended [17, 18], whereas out of pregnancy a
cut-off of < 8 ppm is more standard [19].
Where the expired CO reading is < 8 ppm, or a CO
reading is not available, and the cotinine level is < 10
ng/ml [26], the participant is defined as a biochemically
verified as abstinent. Where the CO reading is < 8 ppm,
or a CO reading is not available, and the cotinine level is
≥ 10 ng/ml and the participant reports use of nicotine
replacement therapy, e-cigarettes or heat-not-burn prod-
ucts, then saliva samples will be also tested for anaba-
sine. Where the anabasine result is < 0.2 ng/ml [27],
then the participant will be defined as a biochemically
verified as abstinent.
Since recruitment to the study is conducted between
34 weeks gestation and 2 weeks postpartum, it is
possible that a few women may relapse after recruitment
and before giving birth. In the analysis for the primary
outcome these women will not be distinguished from
those who have relapsed after the birth. However, we
will report the numbers of women who relapsed before
the birth, separately for the two study groups.
Secondary outcome measures
As a secondary outcome we will assess self-reported,
lapse-free, smoking abstinence from the last quit attempt
in pregnancy until 3 months postpartum, biochemically
validated by an exhaled CO reading of < 8 ppm. Again,
the proportion of abstinent women will be compared be-
tween the intervention and control groups. At both 3
and 12 months, for some women it may not be possible
to conduct a test to biochemically validate self-reported
abstinence (e.g. due to COVID restrictions). Therefore,
as further secondary outcomes we will compare self-
reported abstinence between the study groups at 3 and
12 months (including without biochemical validation as
well as those with validation).
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If a participant is recorded as having relapsed at 3
months postpartum, they will be automatically recorded
as having relapsed for the primary outcome at 12
months postpartum, and will not be followed-up at 12
months.
In addition, in order to understand any differences
between study groups, we will assess the following
measures at three and 12 months postpartum (see
Table 1):
1. Use of nicotine products:
(a) Have you used any nicotine replacement
therapy (NRT) in the last week? Yes/no
(b) If yes, which types of NRT have you mainly
used? (Tick all that apply)
(c) Patch/lozenge/mouth spray/gum/microtabs/
inhalator/nasal spray
(d) Have you used an e-cigarette in the last week?
Yes/no
(e) Have you used a heat-not-burn product in the
last week (e.g. iQOS)? Yes/no
The assessment of use of nicotine products at 12
months postpartum also enabled us to consider the
appropriateness of using a test of saliva cotinine vs
anabasine, to determine smoking status, at this time.
 Smoking in the home: Does anyone living in your
home smoke tobacco? Yes/no
 Partner smoking status: If you have a partner, does
your partner smoke tobacco? Yes/no/not applicable
 Use of additional smoking cessation support beyond
that provided in the trial:
Are you currently receiving any professional help with
stopping smoking other than the help you receive as
part of this research study? Yes/no; if yes, which
organisation is giving you this help?
 Use of the iCO (single-person use) monitor beyond
that required for the research assessments:
Have you used your iCO carbon monoxide monitor at
times other than when asked to do so by your stop
smoking advisor? Yes/no; if yes, on how many days have
you used the iCO in this way since your baby was born?
(Tick one box only) On 1 or 2 days/on 3 to 5 days/on 6
to 10 days/on 11 to 20 days/on more than 20 days
Assessing smoking cessation outcomes during COVID-19
restrictions on face-to-face contact
During COVID-19, for the 3- and 12-month postpartum
outcomes for smoking cessation, if it is not possible to
Table 1 Schedule of assessments




Demographics: age, education, occupation, ethnicity X
Smoking status: self-reported X X X
Time since last smoking X
Expired CO level in ppm X X X
Use of iCO single-person use CO monitor outside of assessments: self-reported X X
Cigarette consumption before pregnancy X
Self-efficacy for smoking cessation X
Use of nicotine products X X X
Smoking in the home X X X
Partner smoking status X X X
Use of additional smoking cessation support X X X




Depression (Edinburgh Postnatal Depression Scale) X
Alcohol consumption: Alcohol Use Disorders Identification-Consumption (AUDIT-C) test X
Expired CO level in ppm X X X
Saliva for cotinine/anabasine test X
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take an expired CO reading during a face-to-face visit,
participants will take a CO reading using a self-
administered/single-person use device (iCOTM Smoker-
lyzer, Bedfont Scientific Ltd.) [28] and send the CO
reading to the stop smoking advisor via an app. There is
recent evidence that the iCO can produce a slightly
higher CO reading than more conventional CO moni-
tors [20]. However, the authors of this study recommend
an optimal cut-off for the iCO of < 6 ppm; therefore, we
decided to retain our more liberal cut-off of < 8 ppm.
If a participant joined the trial before the COVID-19
restrictions and therefore was not sent a self-
administered CO monitor when they were recruited and
a face-to-face CO reading is not possible, then a CO
reading will not be collected at 3 or 12 months follow-
up; at 3 months, abstinence will be self-reported alone
and at 12 months self-reported abstinence will be vali-
dated, where possible, by a saliva test. The participant
will be sent a salivette and instructions to provide a sal-
iva sample and will be advised how to take a saliva sam-
ple during the follow-up call with the stop smoking
advisor. The participant will then be asked to post the
saliva sample to a laboratory for analysis (ABS Labora-
tories, Hertfordshire, UK, https://www.acmgloballab.
com/about-us/our-locations/europe-london-uk). The
follow-up questionnaires will be administered by the
participant’s stop smoking advisor over the phone.
When the COVID-19 restrictions have been lifted, we
will give participants the option of continuing with the
above approach or they can choose to have face-to-face
appointments.
Economic measures
We will examine the incremental cost per quitter for the
financial incentive interventions versus the no incentives
group. We will collect resource and cost data (i.e.
financial incentives, stop smoking service delivery) as
well as considering rates of smoking cessation.
Process evaluation
The process evaluation will collect quantitative data on
recruitment and follow-up rates. In addition, qualitative
data will be collected via a focus group with SSS advi-
sors/managers delivering the intervention and through
interviews with trial participants. This qualitative work
will identify barriers and facilitators to trial recruitment
and adherence and explore the acceptability of study
processes and procedures. Full details of the process
evaluation are reported in Additional file 1.
Baseline measures
In a baseline questionnaire, administered by the SSS
advisor before randomisation, we will assess measures
which have been shown to predict postpartum smoking
relapse [29] and which we would want to ensure are
similar for the three study groups, as potential
confounders of any effects on smoking cessation (see
Table 1). These measures are:
 Age
 Ethnicity
 Highest educational qualification
 Occupation
 Gestation
 Level of cigarette consumption before pregnancy
 Expired CO level in ppm
 Parity (i.e. number of previous pregnancies that have
gone beyond 24 weeks)
 Assessment of any smoking in the home and of
whether partner smokes
 Length of time since last smoking (months/weeks)
 Self-efficacy: rating of ‘How confident are you that
you will continue not to smoke at least until your
baby’s first birthday?’ (not at all confident, slightly
confident, moderately confident, very confident,
extremely confident) [30]
 Depression: Edinburgh Postnatal Depression Scale
[31] (for the item ‘The thought of harming myself
has occurred to me’, if women respond ‘Yes,
quite often’ or ‘sometimes’, they will be referred
to their health visitor, family nurse partnership or
GP)
 Breastfeeding intent [32]
 Alcohol consumption: Alcohol Use Disorders
Identification-Consumption (AUDIT-C) test [33, 34]
 Use of support for smoking cessation beyond what
is provided in the trial
 Whether they recruited a significant other supporter
(SOS) during their pregnancy
 Use of nicotine replacement therapy (NRT) in the
last week and main types of NRT used
 Use of heat-not-burn products in the last week
 Use of e-cigarettes in the last week
Participant timeline {13}
The trial flow diagram is presented in Fig. 1.
Sample size {14}
We estimate that the proposed sample size of 900
women will give 90% power at an alpha threshold of
0.017 to detect a difference in abstinence rates across
any two groups of 13.6% at 12-month follow-up. It is an-
ticipated that the abstinence rate in the control group
will be 9% at 12-month follow-up, that there will be
22.6% abstinence at 12 months follow-up in the 3-
month incentives group and 36.2% abstinence at 12
months follow-up in the 12 months incentives group.
The figure of 9% in the no incentives group is
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conservatively based on the assumption that over 90% of
women without incentives may relapse by 12 months
postpartum [3]. The estimate of 13.6% difference is
based on the group difference found by Tappin and col-
leagues in a study of incentives during pregnancy [34].
The threshold for alpha is reduced to 0.017 to correct
for multiplicity and allow comparisons across the three
arms. This sample size will also give 100% power to de-
tect a linear trend in abstinence across the three groups
(p < 0.05) from control to 12-month intervention.
Recruitment {15}
At the time that women join the Smokefree Pregnancy
programme, which is most commonly following their
first antenatal booking visit at 8–12 weeks gestation,
they will be informed by their stop smoking service
(SSS) advisor that those who are confirmed as abstinent
from smoking at around 36 weeks gestation (acceptable
range, 34 weeks gestation to 2 weeks postpartum) will
be offered the opportunity to join a research study in
which they may or may not be offered shopping
vouchers to remain abstinent through 12 months
postpartum.
Women confirmed as abstinent (CO < 4 ppm) by their
SSS at around 32 weeks gestation will be given or sent a
‘generic’ PIS about the study. We decided to first
provide a generic PIS, explaining that incentives may or
may not be offered, but not giving the specific details of
the three study groups, in order to reduce potential
dissatisfaction and dropout if women are not offered the
highest value of incentives. It will be explained that if
they are still confirmed as abstinent at their 36-week ap-
pointment, and meet other eligibility criteria, they will
have the opportunity to discuss the study and decide if
they want to join. All women confirmed as abstinent at
around 36 weeks gestation by their SSS (acceptable
range, 34 weeks gestation to 2 weeks postpartum), and
meeting other eligibility criteria, will be invited by their
SSS advisor to join the study. If women give birth before
their 36 week appointment they will still be eligible as
Fig. 1 Trial flow diagram
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long they join the study within 2 weeks of the birth of
the baby and meet other eligibility criteria. The SSS ad-
visor will explain that we are running an RCT examining
the effects of offering shopping vouchers on women’s
smoking cessation during the 12 months after their baby
is born and seek consent to participate. See {26a} for a
description of the consent process.
A screening form will be completed by the SSS advisor
to record number of women approached, eligibility,
number of women declining to take part or not eligible,
and reasons for being ineligible or declining, if women
are willing to provide this information.
If a face-to-face visit and/or multiple use CO test is
not possible (e.g. in order to maintain social distancing)
the CO reading to determine eligibility will be taken by
a single-person, self-administered CO monitor, posted to
the woman following her appointment at 32 week’s ges-
tation, and used by the woman at home (iCOTM Smo-
kerlyzer, Bedfont Scientific Ltd.) [28]. The CO reading
will be transferred to the SSS advisor using an app.
Women who do not have a device (e.g. phone) that is
compatible with this app will not be eligible to join the
trial. The baseline questionnaire will be administered by
the stop smoking advisor over the phone. When the
COVID-19 restrictions have been lifted, we will give par-
ticipants the option of continuing with the above ap-
proach or they can choose to have face-to-face
appointments.
Details of those consenting to participate in the trial
will be entered by the SSS advisor on to a secure
University of Stirling online server which will generate a
randomisation code. Some participants may be
disappointed not to be allocated to one of the incentives
groups and the SSS advisors will be trained to respond
appropriately to this. Following randomisation, the
participant’s screening form, baseline questionnaire and
consent form will be sent to the study principal
investigator who will review this documentation and
confirm eligibility.
The patient’s clinical care team (e.g. midwife, health
visitor, GP) will already have been made aware that the
woman is taking part in the Greater Manchester
Smokefree Pregnancy programme; therefore, we will not
be sending a separate letter to patient’s general
physicians (GPs) when they join the trial.
Assignment of interventions: allocation
Sequence generation {16a}
Randomisation and allocation will be carried out by the
trial statistician (CB) at the University of Stirling using
STATA, with randomised permuted blocks and stratified
by site (i.e. hospital trust). Unit of randomisation will be
individual participant, allocated in a ratio of 1:1:1 to the
two intervention groups or control group. Following
completion of the baseline questionnaire, details of
women who consent to participate will be entered by
the SSS advisor into a University of Stirling secure
online server (i.e. randomisation date, participant
birth date, participant initials and site). The SSS will
then be automatically informed of the women’s
unique participant number and treatment allocation
and this information will be given to the participant.
Selection bias will be minimised by ensuring all
consenting women have equal opportunity of being
allocated to each of the study arms.
Concealment mechanism {16b}
Randomisation will use a web-based randomisation
system.
Implementation {16c}
SSS advisors at each site will enrol participants and
request the group allocation.
Assignment of interventions: blinding
Who will be blinded {17a}
Due to the nature of the intervention, participants and
the SSS advisors delivering the intervention will not be
blinded to the treatment received. Nor will SSS advisors
or researchers who ascertain smoking status at 3 and 12
months postpartum be blinded; however, there is low
risk of bias as smoking status is biochemically validated.
Those involved in the data analyses will be blinded to
the group allocation.
Procedure for unblinding if needed {17b}
Participants and SSS staff delivering the intervention are
not blinded.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Data will be collected via questionnaires at baseline and
at three and 12 months postpartum. Questionnaires will
be either self-completed by participants or, during
COVID-19 restrictions, will be administered by SSS ad-
visors over the telephone. Demographic information will
be collected at baseline via questionnaire. CO readings
will be collected at baseline and at 3 and 12 months
postpartum during a face-to-face visit or, during
COVID-19 restrictions, remotely via an app. For those
who report smoking abstinence at 12 months postpar-
tum saliva, for cotinine/anabasine testing, will be col-
lected face-to-face or, during COVID-19 restrictions,
saliva collection kits will be posted to participants and
participants will post the saliva sample to the laboratory.
Ussher et al. Trials          (2021) 22:512 Page 11 of 16
Plans to promote participant retention and complete
follow-up {18b}
In order to maximise the number of participants who
complete follow-ups, especially among those in the con-
trol group and those who have relapsed to smoking, all
participants will be offered a £20 voucher payment, for
completing a follow-up assessment at both 3 months
and 12 months postpartum (i.e. £20 for each assessment).
The assessment includes completion of a questionnaire
and biochemical assessment of smoking status. A previous
UK trial of incentives for smoking cessation in pregnancy
showed that such a payment motivates women to attend
follow-ups [29]. Telephone contact for follow-up will be
attempted on up to five occasions. If a participant has been
asked to post a saliva sample to the laboratory and the sal-
iva sample has not arrived, the participant will be contacted
and reminded to send the sample.
Data management {19}
All trial participants are given an individual trial number
which will be used on all case report forms (CRF) for
that participant. Researchers at the University of Stirling
will enter data from CRFs into the secure trial database.
To check for systematic errors, double data entry will be
conducted for a random selection of 10% of CRFs.
University of Stirling researchers will review CRFs and
the database for range errors and for missing data.
Confidentiality {27}
All collected information will be kept strictly confidential
and will be stored in accordance with the General Data
Protection Regulation (GDPR) and the latest Directive on
Good Clinical Practice (GCP). Confidentiality of patient’s
personal data is ensured by not collecting patient names
on CRFs and limiting access to personal information held
on the databases. At trial enrolment, the participant will
be issued a participant identification number and this will
be the primary identifier for the participant, with
secondary identifiers of month and year of birth and
initials. Any paper copies of personal trial data will be
kept at the participating site in a secure location with
restricted access. Following consent, identifiable data will
be kept in a secure database at each site and at the
University of Stirling, to allow authorised members of the
site team to contact participants in order to arrange
appointments/assessments.
Any paper copies of consent form, with patient name
and signature, will be kept securely at the trial site with
a copy sent to the University of Stirling for monitoring
purposes. Consent forms will not be kept with any
additional patient data.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
None
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
The plan for statistical analysis is reported here in
accordance with guidance for RCTS [35, 36].
We will use descriptive statistics to present the
baseline characteristics of the three study groups.
Descriptive statistics will also be used to report rates of
recruitment, retention and follow-up at 3 months and
12 months postpartum and to report the numbers of
women who relapsed before the birth vs after the birth,
separately for the two study groups. Again, descriptive
statistics will be used to present the following secondary
outcomes at 3 and 12 months postpartum: use of nico-
tine products, smoking in the home, partner smoking
status, use of additional smoking cessation support be-
yond that provided in the trial and use of the iCO (sin-
gle-person use) monitor beyond that required for the
research.
Analyses of smoking status, for primary and secondary
outcomes, will be performed for the intention-to-treat
population and reported in accordance with the Consoli-
dated Standards of Reporting Trials (CONSORT) state-
ment [37, 38], including all women who are randomised
and meet the eligibility criteria. If ineligible persons are
mistakenly randomised into the trial, the independent
trial steering committee will review the case for remov-
ing the participant from the analysis, such that this deci-
sion is unbiased and not influenced by events that
occurred after randomisation (and may therefore be af-
fected by whether patients received experimental or con-
trol treatment) [39].
Women lost to follow-up will be presumed to have
returned to smoking [19]. This assumption is stand-
ard in the smoking cessation literature as the pattern
of missingness is not random. We will compare dif-
ferences in smoking cessation outcomes between all
three treatment groups, using logistic regression ad-
justed for the random effect of site (i.e. NHS Trust),
with statistical significance determined by the
likelihood-ratio test, and with pairwise comparisons
between treatment groups in accordance with the
study objectives, using a p value of 0.017 adjusted for
the three comparisons. The estimate of effect will be
given as the odds ratio and 95% confidence interval
for each of the three comparisons. We will also look
for a linear trend in smoking cessation across the
three groups, by examining the significance (p < 0.05)
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of a linear contrast across the groups from control to
12-month intervention.
All outcomes will be analysed collectively following
the completion of the final follow-up at 12 months post-
partum. A more detailed statistical analysis plan will be
agreed to before the end of data entry and before the
treatment code is broken.
Interim analyses {21b}
There will be no interim analyses.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
We will conduct a secondary-analyses adjusting for key
baseline maternal variables that are predicted to be re-
lated to smoking status (i.e. socio-economic status,
cigarette consumption before pregnancy, depression and
age) and type of smoking cessation service (midwife-led
or not) [40]. We will also conduct sensitivity analysis to
examine the effects of remote (i.e. during COVID-19)
versus face-to-face consultations. We will also consider
whether the women have been supported by a significant
other.
Economic analysis
An incremental cost-effectiveness analysis will be under-
taken, following the NICE guidance for healthcare evalu-
ations [41, 42], comparing the additional costs of the
financial incentive interventions with those of the no in-
centives group, as well as the additional benefits, to give
a cost per additional quitter. The economic evaluation
will use resource and cost data (i.e. financial incentives,
Stop Smoking Service delivery) as well as rates of smok-
ing cessation.
We will document resources consumed that are
related to each intervention, including the cost of
personnel, staff training, materials, space, equipment and
administrative overheads, as well as the costs of the
financial incentives. Data collection methods will include
(i) accounting for staff time using time and effort
reports; (ii) accounting for computer time, mailing and
program costs using an accounting system that has been
created to facilitate real-time aggregation of these costs;
and (iii) using information gathered in the focus group
with staff to determine the amount of time they devote
to tasks related to the incentives intervention. All re-
sources identified during the study will be valued using
appropriate local and national unit cost data. The values
used will be the most up to date at time of analysis, if
unit cost data are obtained from more than one year
then appropriate inflators will be used to transform costs
into a common cost year.
The analysis will adopt a ‘within trial’ approach (i.e. up
to the 12 months follow-up point of the trial). The main
outcome measure used in the economic analysis will be
the study’s primary outcome measure, lapse-free, bio-
chemically validated smoking abstinence at 12 months
postpartum. This will allow us to examine incremental
cost per additional quitter. Multiple imputation will ac-
count for missing data assuming data are missing at ran-
dom, so that missingness can be predicted by other
complete cases.
Costs and effects will be analysed using regression-
based methods to allow for any differences in baseline
characteristics. Incremental costs and effects will be re-
ported. Additionally, if one group is more costly and
more effective than the other we will report incremental
cost-effectiveness ratios (ICERs). Non-parametric boot-
strapping will be used to analyse uncertainty. Uncer-
tainty inherent in the data will be represented by means
of a cost-effectiveness acceptability curve (CEAC). Ana-
lyses will be performed using MS Excel, SPSS and
STATA.
Process evaluation analysis
Full details of the process evaluation analysis are
reported in Additional file 1.
The relationship between the quantitative and
qualitative data will be examined [43].
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
We will use chi-squared tests to compare follow-up rates
between the three study groups to establish whether
there is differential drop out. We will then explore the
effect of alternative assumptions about the pattern of
missing data, through complete case analysis and
through using imputation methods [44].
We will report withdrawal from the intervention and
from the study and reasons for withdrawal, where
known.
Plans to give access to the full protocol, participant-level
data and statistical code {31c}
This document is the full protocol. To access the
participant-level dataset or statistical code, please con-
tact the corresponding author (MU).
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
The Chief Investigator (CI) will have overall
responsibility for the study and its management. The
Trial Management Group (TMG) at the University of
Stirling, including the CI, a statistician, data manager
and researcher, will be responsible for the day-to-day
running of the trial, as well as overseeing data manage-
ment and analyses. The TMG will meet as needed and
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will be supported by and report to a Trial Steering Com-
mittee (TSC). The TSC will have an independent chair-
person and members but also include the TMG, other
trial investigators and a representative of the funders.
The TSC will meet every 6 months and more often if re-
quired. In addition, the site Principal Investigators (PIs)
will meet with the Chief Investigator (CI) every 3
months to discuss progress. The CI will send a monthly
newsletter, including recruitment and follow-up rates, to
the TMG, to all co-investigators and to all site staff.
Composition of the data monitoring committee, its role and
reporting structure {21a}
A separate Data Monitoring and Ethics Committee is
not judged necessary, as we cannot envisage the
intervention having the potential to harm participants.
Adverse event reporting and harms {22}
It is not considered necessary to record or report adverse
events as the intervention being tested involves the offer
of financial incentives (Lovetoshop vouchers) which could
not be a contributory factor in adverse events.
Frequency and plans for auditing trial conduct {23}
The Trial Steering Committee will meet at least every 6
months to audit trial conduct and progress. This will
include independent monitoring of adherence to the
study protocol; approving changes to the study protocol;
reviewing quality assurance indicators; monitoring study
recruitment and the overall timetable; advising, as
required, on specific scientific items that may arise;
compliance with legislation; adherence to research
governance; reporting to funders; and approving
publication and dissemination strategies.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
Amendments will be approved by the research ethics
committee and Health Research Authority. Funders,
sponsors and NHS Research and Development Offices
will be routinely informed of any amendments.
Dissemination plans {31a}
In addition to journal publications and conference
presentations, we will develop a publication and
dissemination policy and will discuss presentations and
dissemination with relevant patient and clinical interest
groups.
Discussion
At present, the majority of women who stop smoking in
pregnancy return to smoking within 12 months of the
birth of their baby. In the UK, there is currently no
standard offer of help to support relapse prevention and
no interventions have been shown to be effective.
Incentive payments to maintain abstinence from
smoking may provide a substantial benefit by reducing
harmful health consequences for the mother and child
and thereby reducing long-term health care costs. The
results of this definitive trial should provide sufficient
data to determine whether it is effective to offer financial
incentives to women to help them avoid relapse to
smoking. This evidence will provide information re-
quired for NICE to consider recommending financial
voucher incentive payments to support pregnant
smokers across the UK to maintain abstinence from the
smoking after the birth of their baby.
Trial status
The FIPPS trial is currently recruiting in four UK centres/
Hospital Trusts in Greater Manchester. Recruitment
began in February 2019 and is due to end In August 2021,
with follow-up completed by September 2022. The trial
has a TSC which has convened five times. During
COVID-19, due to a combination of lack face-to-face
screening of women’s smoking status in pregnancy and re-
duced staffing due to illness or ‘shielding’, fewer women
have joined the pregnancy cessation scheme than ex-
pected and therefore there has been a smaller pool of
women to screen to join the trial. Thus, the trial is behind
target and will not recruit the target of 900 women by Au-
gust 2021. As of June 30th, 2021, 424 participants have
been recruited. Based on recent recruitment rates, we an-
ticipate recruiting approximately 462 women by the end
of August 2021. We do not have the resources to continue
recruiting past this date. This has implications for the
power calculations. Assuming N = 154 in each of the three
study groups and effect sizes as estimated in the original
sample size calculation, then the power for the three com-
parisons, all with an alpha threshold of 0.017, will be:
60% power for 3-month incentives versus 12-month
incentive group comparison
82% power for the no incentives versus 3-month in-
centive group comparison
100% power for the no incentives versus 12-month in-
centive group comparison
The power for examining the significance (p < 0.05) of
a linear contrast across the three groups from control to
12-month intervention will be 100%.
This article is based on protocol version V7.0, 16th
November 2020. For the registered trial protocol and
updates see https://doi.org/10.1186/ISRCTN55218215
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